University of Proportion of Pelvic Inflammatory Disease caused by Chlamydia trachomatis: consistent picture from different methods

Background . Pelvic in fl ammatory disease (PID) is a leading cause of both tubal factor infertility and ectopic pregnancy. Chlamydia trachomatis is an important risk factor for PID, but the proportion of PID cases caused by C. trachomatis is unclear. Estimates of this are required to evaluate control measures. Methods . We consider 5 separate methods of estimating age-group-speci fi c population excess fractions (PEFs) of PID due to C. trachomatis , using routine data, surveys, case-control studies, and randomized controlled trials, and apply these to data from the United Kingdom before introduction of the National Chlamydia Screening Programme. Results . As they are informed by randomized comparisons and national exposure and outcome estimates, our preferred estimates of the proportion of PID cases caused by C. trachomatis are 35% (95% credible interval [CrI], 11% – 69%) in women aged 16 – 24 years and 20% (95% CrI, 6% – 38%) in women aged 16 – 44 years in the United Kingdom. There is a fair degree of consistency between adjusted estimates of PEF, but all have wide 95% CrIs. The PEF decreases from 53.5% (95% CrI, 15.6% – 100%) in women aged 16 – 19 years to 11.5% (95% CrI, 3.0% – 25.7%) in women aged 35 – 44 years. Conclusions . The PEFs of PID due to C. trachomatis decline steeply with age by a factor of around 5-fold between younger and older women. Further studies of the etiology of PID in different age groups are required.

[1]  A. Menon-Johansson,et al.  Sexually transmitted infections in primary care , 2016 .

[2]  M. Price,et al.  The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis. , 2016, Health technology assessment.

[3]  G. Garnett,et al.  Heterogeneity in Risk of Pelvic Inflammatory Diseases After Chlamydia Infection: A Population-Based Study in Manitoba, Canada , 2014, The Journal of infectious diseases.

[4]  J. Ravel,et al.  Microbiome, sex hormones, and immune responses in the reproductive tract: challenges for vaccine development against sexually transmitted infections. , 2014, Vaccine.

[5]  E. Adams,et al.  Time to manage Mycoplasma genitalium as an STI: but not with azithromycin 1 g! , 2014, Current opinion in infectious diseases.

[6]  D. De Angelis,et al.  Risk of Pelvic Inflammatory Disease Following Chlamydia trachomatis Infection: Analysis of Prospective Studies With a Multistate Model , 2013, American journal of epidemiology.

[7]  T. Darville,et al.  Does Bacterial Vaginosis Cause Pelvic Inflammatory Disease? , 2013, Sexually transmitted diseases.

[8]  S. Mehta Systematic Review of Randomized Trials of Treatment of Male Sexual Partners for Improved Bacteria Vaginosis Outcomes in Women , 2012, Sexually transmitted diseases.

[9]  K. Soldan,et al.  Estimation of the Rate of Pelvic Inflammatory Disease Diagnoses: Trends in England, 2000–2008 , 2011, Sexually transmitted diseases.

[10]  N. Low,et al.  Risk of sequelae after Chlamydia trachomatis genital infection in women. , 2010, The Journal of infectious diseases.

[11]  N. Low,et al.  Screening and treatment to prevent sequelae in women with Chlamydia trachomatis genital infection: how much do we know? , 2010, The Journal of infectious diseases.

[12]  S. Kerry,et al.  Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial , 2010, BMJ : British Medical Journal.

[13]  B. Thomas,et al.  Further observations, mainly serological, on a cohort of women with or without pelvic inflammatory disease , 2009, International journal of STD & AIDS.

[14]  F. Cecinato,et al.  Chlamydia trachomatis detection in a population of asymptomatic and symptomatic women: correlation with the presence of serological markers for this infection. , 2008, The new microbiologica.

[15]  L. Nilas,et al.  European guideline for the management of pelvic inflammatory disease , 2007, International journal of STD & AIDS.

[16]  J. Stephenson,et al.  Risk factors associated with pelvic inflammatory disease , 2006, Sexually Transmitted Infections.

[17]  J. Ross Pelvic inflammatory disease. , 2005, Clinical evidence.

[18]  G. Burstein,et al.  Sexually transmitted diseases treatment guidelines , 2003, Current opinion in pediatrics.

[19]  K. Thomas,et al.  Associations between Mycoplasma genitalium, Chlamydia trachomatis and pelvic inflammatory disease , 2003, Journal of clinical pathology.

[20]  Bradley P. Carlin,et al.  Bayesian measures of model complexity and fit , 2002 .

[21]  J. Lave,et al.  Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. , 2002, American journal of obstetrics and gynecology.

[22]  F. Olesen,et al.  Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Andrew Thomas,et al.  WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility , 2000, Stat. Comput..

[24]  J. Stephenson,et al.  Pelvic inflammatory disease epidemiology: what do we know and what do we need to know? , 2000, Sexually transmitted infections.

[25]  J. Paavonen,et al.  Chlamydia trachomatis: impact on human reproduction. , 1999, Human reproduction update.

[26]  Andrew Gelman,et al.  General methods for monitoring convergence of iterative simulations , 1998 .

[27]  Arthur P. Dempster,et al.  The direct use of likelihood for significance testing , 1997, Stat. Comput..

[28]  K. Holmes,et al.  Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. , 1996, The New England journal of medicine.

[29]  P. Wølner-Hanssen,et al.  Silent pelvic inflammatory disease: is it overstated? , 1995, Obstetrics and gynecology.

[30]  G. Ridgway,et al.  Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort , 1995, British journal of obstetrics and gynaecology.

[31]  S. Thompson,et al.  Pelvic Inflammatory Disease and Fertility: A Cohort Study of 1,844 Women with Laparoscopically Verified Disease and 657 Control Women with Normal Laparoscopic Results , 1992, Sexually transmitted diseases.

[32]  S. Cox,et al.  A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. , 1991, American journal of obstetrics and gynecology.

[33]  M. Graffar [Modern epidemiology]. , 1971, Bruxelles medical.